Is there a need for a national or a global apheresis registry?
Indications for apheresis may vary and more than 45 different diagnoses have been reported from various countries. New devices are being developed and, in the beginning their clinical implications and use are limited to detect rare but important side effects. However, to achieve more reliable information on the effects and side effects we need more extensive sampling of data. Collection of such data is considered a safety and quality issue in several countries. However, data is still limited and little is known about therapeutic apheresis practised around the world including the incidence and pattern of adverse events. The establishment of national registries and analyses of data on a global level therefore seems important. Thus the World Apheresis Association (WAA) has initiated a global apheresis registry for therapeutic procedures and collection of e.g., stem cells. The WAA registry is Internet based and the site is at www.iml.umu.se/medicin. A login code to test the registry is needed (AL61TMS). This report deals with the aim of a global registry as well as some comparative data regarding findings of the Canadian, French and Swedish registries.
Stegmayr
Bernd
B
Deparment of Internal Medicine, University Hospital, Norrlands Universitetssjukhus, Umea, Sweden. bernd.stegmayr@medicin.umu.se
Korach
Jean-Michel
JM
Norda
Rut
R
Rock
Gail
G
Fadel
Fouad
F
D001781:Blood Component Removal / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data*; D002170:Canada; D003625:Data Collection / Q000706:statistics & numerical data; D005602:France; D006801:Humans; D010951:Plasma Exchange / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D012042:Registries / Q000706:statistics & numerical data*; D013548:Sweden